Anti-vegf antibodies
AssigneeGenentech, Inc.
InventorsGermaine FUH, Hans-Peter GERBER, Wei-Ching LIANG, Frederic FELLOUSE, Sachdev S. SIDHU, Christian WIESMANN
Life of this patent
Estimating the term…
Abstract
Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
Claims34
1-25. (canceled)
A method of inhibiting angiogenesis in a human or a mouse, the method comprising administering to the human or mouse an antibody capable of binding to human VEGF and mouse VEGF with Kd values within 10-fold of the other, wherein the antibody binds to an epitope comprising residue G88 of human VEGF.
A method of inhibiting angiogenesis in a human or a mouse, the method comprising administering to the human or mouse an antibody capable of binding to human VEGF and mouse VEGF with Kd values within 10-fold of the other, wherein the antibody comprises one or more of the following complementarity determining regions (CDRs):
- (a) a CDR-H1 comprising the amino acid sequence GFAISDYDIH (SEQ ID NO:
- 505);
- (b) a CDR-H2 comprising the amino acid sequence DIAPYAGATAYADSVKG (SEQ ID NO:
- 506);
- (c) a CDR-H3 comprising the amino acid sequence SSYAYYAAMDY (SEQ ID NO:
- 507);
- (d) a CDR-L1 comprising the amino acid sequence RASQSYAYAVA (SEQ ID NO:
- 493);
- (e) a CDR-L2 comprising the amino acid sequence DASYLYS (SEQ ID NO:
- 494);
- and
- (f) a CDR-L3 comprising the amino acid sequence QQAYSSPDT (SEQ ID NO:
- 495).
A method of inhibiting angiogenesis in a human or a mouse, the method comprising administering to the human or mouse an antibody capable of binding to human VEGF and mouse VEGF with Kd values within 10-fold of the other, wherein the antibody comprises one or more of the following complementarity determining regions (CDRs):
- (a) a CDR-H1 comprising the amino acid sequence DYDIH (SEQ ID NO:
- 947);
- (b) a CDR-H2 comprising the amino acid sequence AIAPYSGSTYYADSVK (SEQ ID NO:
- 510);
- (c) a CDR-H3 comprising the amino acid sequence SYAYYSAMDY (SEQ ID NO:
- 511);
- (d) a CDR-L1 comprising the amino acid sequence CRASQASYYDVA (SEQ ID NO:
- 945);
- (e) a CDR-L2 comprising the amino acid sequence AASYLYS (SEQ ID NO:
- 498);
- and
- (f) a CDR-L3 comprising the amino acid sequence CQQYYYAPAT (SEQ ID NO:
- 946).
A method of alleviating cancer or a disease caused by ocular neovascularization in a human or a mouse, the method comprising administering to the human or mouse an antibody capable of binding to human VEGF and mouse VEGF with Kd values within 10-fold of the other, wherein the antibody binds to an epitope comprising residue G88 of human VEGF.
A method of alleviating cancer or a disease caused by ocular neovascularization in a human or a mouse, the method comprising administering to the human or mouse an antibody capable of binding to human VEGF and mouse VEGF with Kd values within 10-fold of the other, wherein the antibody comprises one or more of the following complementarity determining regions (CDRs):
- (a) a CDR-H1 comprising the amino acid sequence GFAISDYDIH (SEQ ID NO:
- 505);
- (b) a CDR-H2 comprising the amino acid sequence DIAPYAGATAYADSVKG (SEQ ID NO:
- 506),
- (c) a CDR-H3 comprising the amino acid sequence SSYAYYAAMDY (SEQ ID NO:
- 507);
- (d) a CDR-L1 comprising the amino acid sequence RASQSYAYAVA (SEQ ID NO:
- 493);
- (e) a CDR-L2 comprising the amino acid sequence DASYLYS (SEQ ID NO:
- 494);
- and
- (f) a CDR-L3 comprising the amino acid sequence QQAYSSPDT (SEQ ID NO:
- 495).
A method of alleviating cancer or a disease caused by ocular neovascularization in a human or a mouse, the method comprising administering to the human or mouse an antibody capable of binding to human VEGF and mouse VEGF with Kd values within 10-fold of the other, wherein the antibody comprises one or more of the following complementarity determining regions (CDRs):
- (a) a CDR-H1 comprising the amino acid sequence DYDIH (SEQ ID NO:
- 947);
- (b) a CDR-H2 comprising the amino acid sequence AIAPYSGSTYYADSVK (SEQ ID NO:
- 510);
- (c) a CDR-H3 comprising the amino acid sequence SYAYYSAMDY (SEQ ID NO:
- 511);
- (d) a CDR-L1 comprising the amino acid sequence CRASQASYYDVA (SEQ ID NO:
- 945);
- (e) a CDR-L2 comprising the amino acid sequence AASYLYS (SEQ ID NO:
- 498);
- and
- (f) a CDR-L3 comprising the amino acid sequence CQQYYYAPAT (SEQ ID NO:
- 946).
Dependencies are inferred from the claim text.